TABLE 1.
Baseline characteristics
| Age, years | 57.7 (49.8–65.3) |
| Male sex | 14 (56) |
| Race/ethnicity | |
| Asian | 2 (8) |
| Black | 4 (16) |
| Caucasian | 12 (48) |
| Hispanic | 5 (20) |
| Unknown | 2 (8) |
| Organ transplant | |
| Kidney | 5 (20) |
| Liver | 2 (8) |
| Lung | 9 (36) |
| Heart | 9 (36) |
| Time from txp to COVID‐19, years | 3.6 (1.2–9.4) |
| Serum creatinine before, mg/dl | 1.2 (0.94–1.3) |
| Serum creatinine after, mg/dl | 1.2 (1.0–1.5) |
| Concomitant drug–drug interactions | 6 (24) |
| Azole antifungals* | 5 (20) |
| Primidone | 1 (4) |
| HMG‐CoA reductase inhibitors | 8 (32) |
| Ticagrelor | 1 (4) |
| Vaccinated | 23 (92) |
| mRNA | 21 (84) |
| Two doses | 5 (21.7) |
| Three doses | 16 (70) |
| Adenovirus vector | 2 (8) |
All values are n (%) or median (IQR, 25–75) unless otherwise specified.
*
Two patients on voriconazole, two patients on clotrimazole, and one patient on posaconazole.